Phospholipids and Alzheimer's disease: Alterations, mechanisms and potential biomarkers

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 1310-1322

  Kosicek, Marko ^a   Hecimovic, Silva ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Alzheimer's disease; Biomarker; Phospholipid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CERAMIDE; GLYCEROPHOSPHOLIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PLASMALOGEN; PLASMALOGEN ETHANOLAMINE; SPHINGOLIPID; SPHINGOMYELIN; SULFATIDE; UNCLASSIFIED DRUG; APP PROTEIN, HUMAN;

AGING; ALZHEIMER DISEASE; BRAIN REGION; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIPID BRAIN LEVEL; LIPID RAFT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; AGED; BRAIN; METABOLISM; PATHOLOGY; PLAQUE, AMYLOID; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOMARKERS; BRAIN; HUMANS; PHOSPHOLIPIDS; PLAQUE, AMYLOID;

EID: 84878491154     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14011310     Document Type: Review

References (69)

1. Veloso, A.; Fernandez, R.; Astigarraga, E.; Barreda-Gomez, G.; Manuel, I.; Giralt, M.T.; Ferrer, I.; Ochoa, B.; Rodriguez-Puertas, R.; Fernandez, J.A. Distribution of Lipids in Human Brain. Anal. Bioanal. Chem. 2011, 401, 89-101.
2. Farooqui, A.A.; Liss, L.; Horrocks, L.A. Neurochemical Aspects of Alzheimers-Disease: Involvement of Membrane Phospholipids. Metab. Brain Dis. 1988, 3, 19-35.
3. Soderberg, M.; Edlund, C.; Kristensson, K.; Dallner, G. Lipid Compositions of Different Regions of the Human-Brain During Aging. J. Neurochem. 1990, 54, 415-423.
4. Svennerholm, L.; Bostrom, K.; Jungbjer, B.; Olsson, L. Membrane-Lipids of Adult Human Brain: Lipid-Composition of Frontal and Temporal-Lobe in Subjects of Age 20 to 100 Years. J. Neurochem. 1994, 63, 1802-1811.
5. Svennerholm, L.; Bostrom, K.; Helander, C.G.; Jungbjer, B. Membrane-Lipids in the Aging Human Brain. J. Neurochem. 1991, 56, 2051-2059.
6. Horrocks, L.A.; VanRollins, M. Yates, A.J.; Lipid Changes in the Ageing Brain. In The Molecular Basis of Neuropathology; Davison, A.N., Thompson, R.H.S., Eds.; Edward Arnold: London, UK, 1981.
7. Ledesma, M.D.; Martin, M.G.; Dotti, C.G. Lipid Changes in the Aged Brain: Effect on Synaptic Function and Neuronal Survival. Prog. Lipid Res. 2012, 51, 23-35.
8. Hirtz, D.; Thurman, D.J.; Gwinn-Hardy, K.; Mohamed, M.; Chaudhuri, A.R.; Zalutsky, R. How Common Are the "Common" Neurologic Disorders? Neurology 2007, 68, 326-337.
9. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H. Huang, Y.Q.; et al; Global Prevalence of Dementia: A Delphi Consensus Study. Lancet 2005, 366, 2112-2117.
10. Wenk, G.L. Neuropathologic Changes in Alzheimer's Disease. J. Clin. Psychiatry 2003, 64, 7-10.
11. Querfurth, H.W.; LaFerla, F.M. Mechanisms of Disease Alzheimer's Disease. N. Eng. J. Med. 2010, 362, 329-344.
12. Blennow, K de Leon, M.J.; Zetterberg, H.; Alzheimer's Disease. Lancet 2006, 368, 387-403.
13. Blennow, K.; Hampel, H.; Weiner, M.; Zetterberg, H. Cerebrospinal Fluid and Plasma Biomarkers in Alzheimer Disease. Nat. Rev. Neurol. 2010, 6, 131-144.
14. Prasad, M.R.; Lovell, M.A.; Yatin, M.; Dhillon, H.; Markesbery, W.R. Regional Membrane Phospholipid Alterations in Alzheimer's Disease. Neurochem. Res. 1998, 23, 81-88.
15. Stokes, C.E.; Hawthorne, J.N. Reduced Phosphoinositide Concentrations in Anterior Temporal Cortex of Alzheimer-Diseased Brains. J. Neurochem. 1987, 48, 1018-1021.
16. Nitsch, R.M.; Blusztajn, J.K.; Pittas, A.G.; Slack, B.E.; Growdon, J.H.; Wurtman, R.J. Evidence for A Membrane Defect in Alzheimer-Disease Brain. Proc. Natl. Acad. Sci. USA 1992, 89, 1671-1675.
17. Wells, K.; Farooqui, A.A.; Liss, L.; Horrocks, L.A. Neural Membrane Phospholipids in Alzheimer Disease. Neurochem. Res. 1995, 20, 1329-1333.
18. Ginsberg, L.; Rafique, S.; Xuereb, J.H.; Rapoport, S.I.; Gershfeld, N.L. Disease and Anatomic Specificity of Ethanolamine Plasmalogen Deficiency in Alzheimers-Disease Brain. Brain Res. 1995, 698, 223-226.
19. Guan, Z.Z.; Wang, Y.A.; Cairns, N.J.; Lantos, P.L.; Dallner, G.; Sindelar, P.J. Decrease and Structural Modifications of Phosphatidylethanolamine Plasmalogen in the Brain With Alzheimer Disease. J. Neuropathol. Exp. Neurol. 1999, 58, 740-747.
20. Igarashi, M.; Ma, K.Z.; Gao, F.; Kim, H.W.; Rapoport, S.I.; Rao, J.S. Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer's Disease Prefrontal Cortex. J. Alzheimers Dis. 2011, 24, 507-517.
21. Pettegrew, J.W.; Panchalingam, K.; Hamilton, R.L.; McClure, R.J. Brain Membrane Phospholipid Alterations in Alzheimer's Disease. Neurochem. Res. 2001, 26, 771-782.
22. Han, X.L.; Holtzman, D.M. Mckeel, D.W.; Plasmalogen Deficiency in Early Alzheimer's Disease Subjects and in Animal Models: Molecular Characterization Using Electrospray Ionization Mass Spectrometry. J. Neurochem. 2001, 77, 1168-1180.
23. Han, X.; Holtzman, M.; McKeel, D.W., Jr.; Kelley, J.; Morris, J.C. Substantial Sulfatide Deficiency and Ceramide Elevation in Very Early Alzheimer's Disease: Potential Role in Disease Pathogenesis. J. Neurochem. 2002, 82, 809-818.
24. He, X.; Huang, Y.; Li, B.; Gong, C.X.; Schuchman, E.H. Deregulation of Sphingolipid Metabolism in Alzheimer's Disease. Neurobiol. Aging 2010, 31, 398-408.
25. Cutler, R.G.; Kelly, J.; Storie, K.; Pedersen, W.A.; Tammara, A.; Hatanpaa, K.; Troncoso, J.C.; Mattson, M.P. Involvement of Oxidative Stress-Induced Abnormalities in Ceramide and Cholesterol Metabolism in Brain Aging and Alzheimer's Disease. Proc. Natl. Acad. Sci. USA 2004, 101, 2070-2075.
26. Bandaru, V.V.; Troncoso, J.; Wheeler, D.; Pletnikova, O.; Wang, J.; Conant, K.; Haughey, N.J. ApoE4 Disrupts Sterol and Sphingolipid Metabolism in Alzheimer's, but Not Normal Brain. Neurobiol. Aging 2009, 30, 591-599.
27. Han, X.L. Potential Mechanisms Contributing to Sulfatide Depletion at the Earliest Clinically Recognizable Stage of Alzheimer's Disease: A Tale of Shotgun Lipidomics. J. Neurochem. 2007, 103, 171-179.
28. Haughey, N.J.; Bandaru, V.V.R.; Bae, M.; Mattson, M.P. Roles for Dysfunctional Sphingolipid Metabolism in Alzheimer's Disease Neuropathogenesis. Biochim. Biophys. Acta Mol. Cell Biol Lipids 2010, 1801, 878-886.
29. Van Echten-Deckert, G.; Walter, J. Sphingolipids: Critical Players in Alzheimer's Disease. Prog. Lipid Res. 2012, 51, 378-393.
30. Mulder, C.; Wahlund, L.O.; Teerlink, T.; Blomberg, M.; Veerhuis, R.; van Kamp, G.J.; Scheltens, P.; Scheffer, P.G. Decreased Lysophosphatidylcholine/Phosphatidylcholine Ratio in Cerebrospinal Fluid in Alzheimer's Disease. J. Neural Transm. 2003, 110, 949-955.
31. Walter, A.; Korth, U.; Hilgert, M.; Hartmann, J.; Weichel, O.; Hilgert, M.; Fassbender, K.; Schmitt, A.; Klein, J. Glycerophosphocholine Is Elevated in Cerebrospinal Fluid of Alzheimer Patients. Neurobiol. Aging 2004, 25, 1299-1303.
32. Satoi, H.; Tomimoto, H.; Ohtani, R.; Kitano, T.; Kondo, T.; Watanabe, M.; Oka, N.; Akiguchi, I.; Furuya, S. Hirabayashi, Y.; et al; Astroglial Expression of Ceramide in Alzheimer's Disease Brains: a Role During Neuronal Apoptosis. Neuroscience 2005, 130, 657-666.
33. Han, X.; Fagan, A.M.; Cheng, H.; Morris, J.C.; Xiong, C.; Holtzman, D.M. Cerebrospinal Fluid Sulfatide Is Decreased in Subjects With Incipient Dementia. Ann. Neurol. 2003, 54, 115-119.
34. Kosicek, M.; Kirsch, S.; Bene, R.; Trkanjec, Z.; Titlic, M.; Bindila, L.; Peter-Katalinic, J.; Hecimovic, S. Nano-HPLC-MS Analysis of Phospholipids in Cerebrospinal Fluid of Alzheimer's Disease Patients-A Pilot Study. Anal. Bioanal. Chem. 2010, 398, 2929-2937.
35. Kosicek, M.; Zetterberg, H.; Andreasen, N.; Peter-Katalinic, J.; Hecimovic, S. Elevated Cerebrospinal Fluid Sphingomyelin Levels in Prodromal Alzheimer's Disease. Neurosci. Lett. 2012, 516, 302-305.
36. Mielke, M.M.; Bandaru, V.V.; Haughey, N.J.; Rabins, P.V.; Lyketsos, C.G.; Carlson, M.C. Serum Sphingomyelins and Ceramides Are Early Predictors of Memory Impairment. Neurobiol. Aging 2010, 31, 17-24.
37. Mielke, M.M.; Haughey, N.J.; Bandaru, V.V.R.; Schech, S.; Carrick, R.; Carlson, M.C.; Mori, S.; Miller, M.I.; Ceritoglu, C.; Brown, T.; et al. Plasma Ceramides Are Altered in Mild Cognitive Impairment and Predict Cognitive Decline and Hippocampal Volume Loss. Alzheimer's Dementia 2010, 6, 378-385.
38. Mielke, M.M.; Lyketsos, C.G. Alterations of the Sphingolipid Pathway in Alzheimer's Disease: New Biomarkers and Treatment Targets? Neuromol. Med. 2010, 12, 331-340.
39. Mattsson, N.; Zetterberg, H.; Hansson, O.; Andreasen, N.; Parnetti, L.; Jonsson, M.; Herukka, S.K.; van der Flier, W.M.; Blankenstein, M.A.; Ewers, M.; et al. CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. J. Am. Med. Assoc. 2009, 302, 385-393.
40. Cheng, H.; Xu, J.; Mckeel, D.W.; Han, X. Specificity and Potential Mechanism of Sulfatide Deficiency in Alzheimer's Disease: An Electrospray Ionization Mass Spectrometric Study. Cell. Mol. Biol. 2003, 49, 809-818.
41. Fredman, P.; Wallin, A.; Blennow, K.; Davidsson, P.; Gottfries, C.G.; Svennerholm, L. Sulfatide As A Biochemical Marker in Cerebrospinal Fluid of Patients With Vascular Dementia. Acta Neurol Scand. 1992, 85, 103-106.
42. Jonsson, M.; Zetterberg, H.; Rolstad, S.; Edman, A.; Gouw, A.A.; Bjerke, M.; Lind, K.; Blennow, K.; Pantoni, L.; Inzitari, D.; et al. Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions-The LADIS Study. Dementia Geriatr. Cognit. Disord. 2012, 34, 61-67.
43. Han, X. Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimer's Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimer's Disease. Curr. Alzheimer Res. 2005, 2, 65-77.
44. Strittmatter, W.J.; Roses, A.D. Apolipoprotein E and Alzheimer's Disease. Ann.Rev. Neurosci. 1996, 19, 53-77.
45. Verghese, P.B.; Castellano, J.M.; Holtzman, D.M. Apolipoprotein E in Alzheimer's Disease and Other Neurological Disorders. Lancet Neurol. 2011, 10, 241-252.
46. Keene, C.D.; Cudaback, E.; Li, X.W.; Montine, K.S.; Montine, T.J. Apolipoprotein E Isoforms and Regulation of the Innate Immune Response in Brain of Patients with Alzheimer's Disease. Curr. Opin. Neurobiol. 2011, 21, 920-928.
47. Han, X.L.; Cheng, H.; Fryer, J.D.; Fagan, A.M.; Holtzman, D.M. Novel Role for Apolipoprotein E in the Central Nervous System-Modulation of Sulfatide Content. J. Biol. Chem 2003, 278, 8043-8051.
48. Han, X.L. Multi-Dimensional Mass Spectrometry-Based Shotgun Lipidomics and the Altered Lipids at the Mild Cognitive Impairment Stage of Alzheimer's Disease. Biochim. Biophys. Acta Mol Cell Biol. Lipids 2010, 1801, 774-783.
49. Bartke, N.; Hannun, Y.A. Bioactive Sphingolipids: Metabolism and Function. J. Lipid Res. 2009, 50, S91-S96.
50. Colombaioni, L. Garcia-Gil, M.; Sphingolipid Metabolites in Neural Signalling and Function. Brain. Res. Rev. 2004, 46, 328-355.
51. Katsel, P.; Li, C., Haroutunian, V.; Gene Expression Alterations in the Sphingolipid Metabolism Pathways During Progression of Dementia and Alzheimer's Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer's Disease?. Neurochem Res. 2007, 32, 845-856.
52. Lee, J.T.; Xu, J.; Lee, J.M.; Ku, G.; Han, X.L.; Yang, D.I.; Chen, S.W.; Hsu, C.Y. Amyloid-Beta Peptide Induces Oligodendrocyte Death by Activating the Neutral Sphingomyelinase-Ceramide Pathway. J. Cell Biol. 2004, 164, 123-131.
53. Patil, S.; Melrose, J.; Chan, C. Involvement of Astroglial Ceramide in Palmitic Acid-Induced Alzheimer-Like Changes in Primary Neurons. Eur. J. Neurosci. 2007, 26, 2131-2141.
54. Puglielli, L.; Ellis, B.C.; Saunders, A.J. Kovacs, D.M. Ceramide Stabilizes Beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 and Promotes Amyloid Beta-Peptide Biogenesis. J. Biol. Chem. 2003, 278, 19777-19783.
55. Horres, C.R.; Hannun, Y.A. The Roles of Neutral Sphingomyelinases in Neurological Pathologies. Neurochem. Res. 2012, 37, 1137-1149.
56. Pike, L.J. The Challenge of Lipid Rafts. J. Lipid Res. 2009, 50, S323-S328.
57. Pike, L.J.: Lipid Rafts: Heterogeneity on the High Seas. Biochem. J. 2004, 378, 281-292.
58. Ehehalt, R.; Keller, P.; Haass, C.; Thiele, C.; Simons, K. Amyloidogenic Processing of the Alzheimer Beta-Amyloid Precursor Protein Depends on Lipid Rafts. J. Cell Biol. 2003, 160, 113-123.
59. Riddell, D.R.; Christie, G.; Hussain, I.; Dingwall, C. Compartmentalization of Beta-Secretase (Asp2) into Low-Buoyant Density, Noncaveolar Lipid Rafts. Curr. Biol. 2001, 11, 1288-1293.
60. Vetrivel, K.S.; Cheng, H.P.; Lin, W.; Sakurai, T.; Li, T.; Nukina, N.; Wong, P.C.; Xu, H.X.; Thinakaran, G. Association of Gamma-Secretase With Lipid Rafts in Post-Golgi and Endosome Membranes. J. Biol. Chem. 2004, 279, 44945-44954.
61. Wahrle, S.; Das, P.; Nyborg, A.C.; McLendon, C.; Shoji, M.; Kawarabayashi, T.; Younkin, L.H.; Younkin, S.G.; Golde, T.E. Cholesterol-Dependent Gamma-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains. Neurobiol. Dis. 2002, 9, 11-23.
62. Kosicek, M.; Malnar, M.; Goate, A.; Hecimovic, S. Cholesterol Accumulation in Niemann Pick Type C (NPC) Model Cells Causes a Shift in APP Localization to Lipid Rafts. Biochem. Biophys. Res. Commun. 2010, 393, 404-409.
63. Cordy, J.M.; Hussain, I.; Dingwall, C.; Hooper, N.M.; Turner, A.J. Exclusively Targeting Beta-Secretase to Lipid Rafts by GPI-Anchor Addition Up-Regulates Beta-Site Processing of the Amyloid Precursor Protein. Proc. Natl. Acad. Sci. USA 2003, 100, 11735-11740.
64. Vetrivel, K.S.; Meckler, X.; Chen, Y.; Nguyen, P.D.; Seidah, N.G.; Vassar, R.; Wong, P.C.; Fukata, M.; Kounnas, M.Z.; Thinakaran, G. Alzheimer Disease A Beta Production in the Absence of S-Palmitoylation-Dependent Targeting of BACE1 to Lipid Rafts. J. Biol. Chem. 2009, 284, 3793-3803.
65. Cheng, H.P.; Vetrivel, K.S.; Drisdel, R.C.; Meckler, X.; Gong, P.; Leem, J.Y.; Li, T.; Carter, M.; Chen, Y Nguyen, P. et al. S-Palmitoylation of Gamma-Secretase Subunits Nicastrin and APH-1. J. Biol. Chem. 2009, 284, 1373-1384.
66. Rajendran, L.; Schneider, A.; Schlechtingen, G.; Weidlich, S.; Ries, J.; Braxmeier, T.; Schwille, P.; Schulz, J.B.; Schroeder, C. Simons, M.;et al.; Efficient Inhibition of the Alzheimer's Disease Beta-Secretase by Membrane Targeting. Science 2008, 320, 520-523.
67. Hartmann, T.; Kuchenbecker, J.; Grimm, M.O. Alzheimer's Disease: The Lipid Connection. J. Neurochem. 2007, 103, 159-170.
68. Martins, I.J.; Berger, T.; Sharman, M.J.; Verdile, G.; Fuller, S.J.; Martins, R.N. Cholesterol Metabolism and Transport in the Pathogenesis of Alzheimer's Disease. J. Neurochem. 2009, 111, 1275-1308.
69. Stefani, M.; Liguri, G. Cholesterol in Alzheimer's Disease: Unresolved Questions. Curr. Alzheimer Res. 2009, 6, 15-29.